Relapsed and/or Refractory Multiple Myeloma
Conditions
Keywords
Drug Therapy
Brief summary
The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics (PK) of ixazomib alone or in combination with lenalidomide and dexamethasone (Rd), and antitumor activity of ixazomib in participants with RRMM.
Detailed description
The drug being tested in this study is called ixazomib. This study will evaluate the tolerability, safety, and PK of ixazomib administered alone or in combination with lenalidomide and dexamethasone in participants with relapsed and/or refractory multiple myeloma. This study will enroll approximately 24 participants (3 to 6 participants in each dose-escalation cohort). Participants will be assigned to receive treatment in one of the four treatment cohorts: * Cohort 1: Ixazomib 4.0 mg * Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone * Cohort 3: Ixazomib 5.5 mg * Cohort 4: Ixazomib 5.5 mg + Lenalidomide and Dexamethasone This multi-center trial will be conducted in Japan. The overall time to participate in this study is approximately 7 years. Participants will make a final visit 29 days after receiving their last dose of drug for a follow-up assessment.
Interventions
DRUGIxazomib
Ixazomib capsules.
DRUGLenalidomide
Lenalidomide capsules.
DRUGDexamethasone
Dexamethasone tablets.
Sponsors
Takeda
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Japanese participants with multiple myeloma according to diagnostic criteria. 2. Previously treated with 2 or more regimens including all the following drugs; bortezomib, thalidomide or lenalidomide, corticosteroids. 3. Who have relapsed following the previous therapy or failed to continue the treatment due to their intolerability to the last treatment regimen for myeloma. 4. Measurable disease defined by at least one of the following 3 measurements; Serum M-protein: greater than or equal to (\>=) 1 gram per deciliter (g/dL) (\>= 10 gram per liter \[g/L\]), Urine M-protein: \>= 200 mg/24 hours, Serum free light chain (FLC) assay: involved FLC level \>= 10 milligram per deciliter (mg/dL) (\>= 100 milligram per liter \[mg/L\]), provided that the serum FLC ratio is abnormal. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. 6. 20 years or older at giving their informed consent. 7. Must be able to stay in the hospital for Cycle 1 treatment. 8. Must meet the following laboratory criteria at screening; Absolute neutrophil count (ANC): \>=1,000 per cubic millimeter (/mm\^3), Platelet count: \>=75,000/mm\^3, Total bilirubin: \<=1.5\* the upper limit of normal range (ULN), Alanine aminotransferase (ALT) and aspartate aminotransferase (AST): less than or equal to (\<=) 3\* ULN, Creatinine clearance: calculated by using Cockcroft-Gault formula; MLN9708 monotherapy cohort: \>=30 milliliter per minute (mL/min); MLN9708 with Rd cohort: \>=60 mL/min. 9. Recovered (\<= Grade 1) from the toxicities of the prior treatments. ANC \>=1,000/mm\^3. 10. Life expectancy of at least 3 months, in the judgment of the investigator. 11. Conforming to proper management guidelines of lenalidomide (MLN9708 with Rd cohort only).
Exclusion criteria
1. With plasmacytoma only. 2. With plasma cell leukemia. 3. With central nervous system invasion. 4. Radiotherapy within 14 days before enrollment. 5. Other anti-tumor drug administration within 21 days before enrollment. 6. Other investigational products administration within 21 days before enrollment (60 days from the last dose for carfilzomib). 7. Antibody treatment within 42 days before enrollment. 8. Systemic treatment with potent cytochrome P450 (CYP) isozyme 1A2 inhibitors (fluvoxamine, enoxacin), potent CYP3A inhibitors (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole), or potent CYP3A inducers (rifampin, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of foods containing Ginkgo biloba extract, St. John's Wort, or grapefruit within 14 days before enrollment. 9. Treatment with corticosteroids greater than (\>) 10 mg of prednisolone per day. Inhaled and topical steroids are permitted. 10. Peripheral neuropathy \>=Grade 2. 11. Diarrhea \>= Grade 2. 12. Major surgery requiring general anesthesia within 14 days before enrollment. 13. Infection requiring systemic antibiotic treatment or other serious infections within 14 days before enrollment. 14. Evidence of concurrent uncontrolled cardiovascular conditions including hypertension, cardiac arrhythmias, New York Heart Association (NYHA) Class III or worse congestive heart failure, angina, myocardial infarction, or cerebral infarction within 6 months before enrollment. 15. Corrected QT interval (QTc) \> 470 milliseconds on a 12-lead ECG obtained during the screening period. 16. Tested positive for human immunodeficiency virus (HIV) antibody, hepatitis B virus surface antigen (HBs antigen), or hepatitis C virus (HCV) antibody during the screening period. 17. Hypersensitivity to MLN9708 (including excipients), boron, or boron-containing drugs. 18. Hypersensitivity to lenalidomide, or dexamethasone, or excipients contained in the formulation of each drug (MLN9708 with Rd cohort only). 19. Known gastrointestinal diseases (difficulty swallowing, inflamed gastroenteritis, and Crohn disease), or gastrointestinal procedure (endoscopic procedure is permitted), that could interfere with the oral absorption or tolerance of the study treatment. 20. Uncontrolled diabetes mellitus. 21. A history of interstitial lung disease or lung fibrosis, or a current complication of interstitial lung disease or lung fibrosis diagnosed by diagnostic chest imaging. 22. Prior or current complications of deep vein thrombosis or pulmonary embolism (MLN9708 with Rd cohort only). 23 Diagnosed or treated for another malignancy within 2 years before the first dose or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have complete resection. 24\. Who do not consent to use adequate contraceptive precautions (example, condoms and oral contraceptives) during the following term: * For women with childbearing potential, from when giving their consent through 3 months after the last dose of MLN9708, dexamethasone, or lenalidomide * For men having their partners with childbearing potential, from giving their consent through 4 months after last dose of MLN9708, dexamethasone, or lenalidomide. 25\. Pregnant (example, positive for pregnancy test) or lactating. Lactation is prohibited from the first dose through 6 months after the last dose of MLN9708, dexamethasone, and lenalidomide. 26\. Use of an investigational medical device within 28 days before enrollment. 27. Any inabilities that could potentially interfere with the consent or completion of treatment according to this protocol. 28\. Having difficulties in participation to this study by the investigator's judgment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cmax: Maximum Observed Plasma Concentration for Ixazomib | Days 1 and 15 of Cycle 1: pre-dose and at multiple time points (15, 30, 60, and 90 minutes and 2, 4, 8, 24, 48, 96, and 168 hours) post-dose (Cycle length=28 days) | — |
| Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) | From Cycle 1 Day 1 until Cycle 2 Day 1 (Cycle length is equal to [=] 28 days) | DLT:Any following adverse events (AEs) possibly related to ixazomib assessed by Common Terminology Criteria for AEs (CTCAE) version 4.03; Grade 4 neutropenia/thrombocytopenia lasting \>7 consecutive days; Grade 3/greater neutropenia with fever/infections; Grade 3/greater thrombocytopenia with clinically significant bleeding; platelet count less than (\<)10,000 per cubic meter(/mm\^3); Grade 2 peripheral neuropathy with pain/Grade 3 or greater peripheral neuropathy; Grade 3/greater nonhematologic toxicities with exceptions of arthralgia/myalgia, fatigue lasting \<7 days manageable nausea/emesis with antiemetic prophylaxis, diarrhea that is controlled with supportive care; treatment delay of \>14 days at start of Cycle 2 due to failure of hematologic/nonhematologic recovery; Other Grade 2/greater ixazomib related nonhematologic toxicities required permanent discontinuation of ixazomib;Inability to receive at least 80% of planned lenalidomide doses due to the AEs related to ixazomib. |
| Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE) | Baseline up to 29 days after last dose of study drug (up to Cycle 87 Day 44) (Each Cycle length=28 days) | — |
| Number of Participants With Grade 3 or Higher TEAE Related to Body Weight | Baseline up to 29 days after last dose of study drug (up to Cycle 87 Day 44) (Each Cycle length=28 days) | Body weight abnormalities were graded using the CTCAE version 4.03. as: Grade 1 (Mild, asymptomatic or mild symptoms); Grade 2 (Moderate, minimal, local or noninvasive intervention indicated); Grade 3 (Severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated); Grade 4 (Life-threatening consequences, urgent intervention indicated); Grade 5 (Death related to AE). |
| Number of Participants With Grade 3 or Higher TEAE Related to Vital Signs | Baseline up to 29 days after last dose of study drug (up to Cycle 87 Day 44) (Each Cycle length=28 days) | Vital signs were graded using the CTCAE version 4.03. as: Grade 1 (Mild, asymptomatic or mild symptoms); Grade 2 (Moderate, minimal, local or noninvasive intervention indicated); Grade 3 (Severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated); Grade 4 (Life-threatening consequences, urgent intervention indicated); Grade 5 (Death related to AE). |
| Number of Participants With Grade 3 or Higher TEAE Related to 12-lead Electrocardiograms (ECGs) | Baseline up to 29 days after last dose of study drug (up to Cycle 87 Day 44) (Each Cycle length=28 days) | 12-lead ECGs were graded using the CTCAE version 4.03. as: Grade 1 (Mild, asymptomatic or mild symptoms); Grade 2 (Moderate, minimal, local or noninvasive intervention indicated); Grade 3 (Severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated); Grade 4 (Life-threatening consequences, urgent intervention indicated); Grade 5 (Death related to AE). |
| Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Baseline up to 29 days after last dose of study drug (up to Cycle 87 Day 44) (Each Cycle length=28 days) | Laboratory tests abnormalities were graded using the CTCAE version 4.03. as: Grade 1 (Mild, asymptomatic or mild symptoms); Grade 2 (Moderate, minimal, local or noninvasive intervention indicated); Grade 3 (Severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated); Grade 4 (Life-threatening consequences, urgent intervention indicated); Grade 5 (Death related to AE). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Who Achieved Complete Response (CR), Very Good Partial Response (VGPR), and Partial Response (PR) | Baseline up to 29 days after last dose of study drug (up to Cycle 87 Day 44) (Each Cycle length=28 days) | Number of participants who achieved CR, PR, VGPR were assessed in accordance to International Myeloma Working Group Uniform Response Criteria for Multiple Myeloma. CR: No immunofixation on serum and urine, disappearance of soft tissue plasmacytomas and \<5% plasma cells in bone marrow. Normal serum free light chain (SFLC) ratio if disease measurable only by SFLC. VGPR: Serum and urine M-protein detectable by immunofixation but not electrophoresis or greater than or equal to (\>=) 90% decrease in serum M-protein with urine M-protein \<100 milligram per 24 hours (mg/24 hrs). If disease measurable only by SFLC, \>= 90% decrease in the difference between involved and uninvolved FLC levels (dFLC). PR: \>= 50% reduction of serum M-protein and \>= 90% reduction in urine M-protein or to \<200 mg/24 hrs, or a \>= 50% decrease in dFLC. A \>=50% decrease in the size of soft tissue plasmacytomas present at baseline |
Participant flow
Recruitment details
Participants took part in the study at 5 investigative sites in Japan from 05 June 2012 to 15 February 2019.
Pre-assignment details
Relapsed and/or refractory multiple myeloma (RRMM) participants were enrolled to receive ixazomib 4.0 milligram (mg) in: Cohort 1 and along with lenalidomide 25 milligram per day (mg/day) and dexamethasone 40 mg/day (Rd) in Cohort 2. Study was terminated after completion of Cohorts 1 and 2 due to business decision; no safety or efficacy concerns.
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1: Ixazomib 4.0 mg Ixazomib 4.0 mg, capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle for up to Cycle 87. | 7 |
| Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone Ixazomib 4.0 mg, capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle along with lenalidomide 25 mg/day, capsules, orally, once, from Days 1 to 21 and dexamethasone 40 mg/day, tablets, orally, once, on Days 1, 8, 15, and 22 in a 28-day treatment cycle for up to Cycle 62. | 7 |
| Total | 14 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 1 | 2 |
| Overall Study | Progressive Disease | 3 | 1 |
| Overall Study | Protocol Violation | 0 | 1 |
| Overall Study | Study Terminated by Sponsor | 1 | 0 |
| Overall Study | Symptomatic Deterioration | 1 | 1 |
| Overall Study | Withdrawal by Subject | 1 | 2 |
Baseline characteristics
| Characteristic | Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Total | Cohort 1: Ixazomib 4.0 mg |
|---|---|---|---|
| Age, Continuous | 60.3 years STANDARD_DEVIATION 5.82 | 61.9 years STANDARD_DEVIATION 5.14 | 63.4 years STANDARD_DEVIATION 4.2 |
| Body Surface Area (BSA) | 1.628 square meter (m^2) STANDARD_DEVIATION 0.1652 | 1.607 square meter (m^2) STANDARD_DEVIATION 0.1504 | 1.585 square meter (m^2) STANDARD_DEVIATION 0.1438 |
| Eastern Cooperative Oncology Group Performance Status 0 | 6 Participants | 12 Participants | 6 Participants |
| Eastern Cooperative Oncology Group Performance Status 1 | 0 Participants | 1 Participants | 1 Participants |
| Eastern Cooperative Oncology Group Performance Status 2 | 1 Participants | 1 Participants | 0 Participants |
| Height | 165.29 centimeter (cm) STANDARD_DEVIATION 8.245 | 160.89 centimeter (cm) STANDARD_DEVIATION 9.015 | 156.49 centimeter (cm) STANDARD_DEVIATION 7.932 |
| Medical and Surgical History Had history | 7 Participants | 14 Participants | 7 Participants |
| Medical and Surgical History No history | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 7 Participants | 14 Participants | 7 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 0 Participants | 0 Participants | 0 Participants |
| Region of Enrollment Japan | 7 Participants | 14 Participants | 7 Participants |
| Sex: Female, Male Female | 2 Participants | 6 Participants | 4 Participants |
| Sex: Female, Male Male | 5 Participants | 8 Participants | 3 Participants |
| Weight | 58.01 kilogram (kg) STANDARD_DEVIATION 9.688 | 58.01 kilogram (kg) STANDARD_DEVIATION 8.745 | 58.01 kilogram (kg) STANDARD_DEVIATION 8.477 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 7 | 0 / 7 |
| other Total, other adverse events | 7 / 7 | 7 / 7 |
| serious Total, serious adverse events | 4 / 7 | 2 / 7 |
Outcome results
Primary
Cmax: Maximum Observed Plasma Concentration for Ixazomib
Time frame: Days 1 and 15 of Cycle 1: pre-dose and at multiple time points (15, 30, 60, and 90 minutes and 2, 4, 8, 24, 48, 96, and 168 hours) post-dose (Cycle length=28 days)
Population: The pharmacokinetic (PK) analysis set consisted of all participants who received at least one dose of ixazomib and has evaluable PK data. The PK analysis set where data at specified time points was available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Cohort 1: Ixazomib 4.0 mg | Cmax: Maximum Observed Plasma Concentration for Ixazomib | Day 1 | 65.3 nanogram per milliliter (ng/mL) | Standard Deviation 54.6 |
| Cohort 1: Ixazomib 4.0 mg | Cmax: Maximum Observed Plasma Concentration for Ixazomib | Day 15 | 68.8 nanogram per milliliter (ng/mL) | Standard Deviation 59.9 |
| Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Cmax: Maximum Observed Plasma Concentration for Ixazomib | Day 1 | 32.9 nanogram per milliliter (ng/mL) | Standard Deviation 19.3 |
| Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Cmax: Maximum Observed Plasma Concentration for Ixazomib | Day 15 | 34.5 nanogram per milliliter (ng/mL) | Standard Deviation 42 |
Primary
Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)
Time frame: Baseline up to 29 days after last dose of study drug (up to Cycle 87 Day 44) (Each Cycle length=28 days)
Population: The safety analysis set consisted of all participants who received at least one dose of ixazomib.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1: Ixazomib 4.0 mg | Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE) | 7 Participants |
| Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE) | 7 Participants |
Primary
Number of Participants Who Experienced Dose Limiting Toxicities (DLTs)
DLT:Any following adverse events (AEs) possibly related to ixazomib assessed by Common Terminology Criteria for AEs (CTCAE) version 4.03; Grade 4 neutropenia/thrombocytopenia lasting \>7 consecutive days; Grade 3/greater neutropenia with fever/infections; Grade 3/greater thrombocytopenia with clinically significant bleeding; platelet count less than (\<)10,000 per cubic meter(/mm\^3); Grade 2 peripheral neuropathy with pain/Grade 3 or greater peripheral neuropathy; Grade 3/greater nonhematologic toxicities with exceptions of arthralgia/myalgia, fatigue lasting \<7 days manageable nausea/emesis with antiemetic prophylaxis, diarrhea that is controlled with supportive care; treatment delay of \>14 days at start of Cycle 2 due to failure of hematologic/nonhematologic recovery; Other Grade 2/greater ixazomib related nonhematologic toxicities required permanent discontinuation of ixazomib;Inability to receive at least 80% of planned lenalidomide doses due to the AEs related to ixazomib.
Time frame: From Cycle 1 Day 1 until Cycle 2 Day 1 (Cycle length is equal to [=] 28 days)
Population: The DLT analysis set consisted of DLT evaluable participants who received at least one dose of ixazomib.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1: Ixazomib 4.0 mg | Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) | 1 Participants |
| Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) | 1 Participants |
Primary
Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities
Laboratory tests abnormalities were graded using the CTCAE version 4.03. as: Grade 1 (Mild, asymptomatic or mild symptoms); Grade 2 (Moderate, minimal, local or noninvasive intervention indicated); Grade 3 (Severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated); Grade 4 (Life-threatening consequences, urgent intervention indicated); Grade 5 (Death related to AE).
Time frame: Baseline up to 29 days after last dose of study drug (up to Cycle 87 Day 44) (Each Cycle length=28 days)
Population: The safety analysis set consisted of all participants who received at least one dose of ixazomib.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1: Ixazomib 4.0 mg | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 3: Neutrophils low | 4 Participants |
| Cohort 1: Ixazomib 4.0 mg | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 3: Potassium low | 1 Participants |
| Cohort 1: Ixazomib 4.0 mg | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 3: Platelets low | 0 Participants |
| Cohort 1: Ixazomib 4.0 mg | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 3: Phosphate low | 1 Participants |
| Cohort 1: Ixazomib 4.0 mg | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 3: Leukocytes low | 3 Participants |
| Cohort 1: Ixazomib 4.0 mg | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 4: Lymphocytes low | 3 Participants |
| Cohort 1: Ixazomib 4.0 mg | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 4: Neutrophils low | 0 Participants |
| Cohort 1: Ixazomib 4.0 mg | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 3: Albumin low | 1 Participants |
| Cohort 1: Ixazomib 4.0 mg | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 4: Leukocytes low | 0 Participants |
| Cohort 1: Ixazomib 4.0 mg | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 3: Hemoglobin low | 2 Participants |
| Cohort 1: Ixazomib 4.0 mg | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 3: Corrected calcium high | 0 Participants |
| Cohort 1: Ixazomib 4.0 mg | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 4: Platelets low | 3 Participants |
| Cohort 1: Ixazomib 4.0 mg | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 3: Lymphocytes low | 3 Participants |
| Cohort 1: Ixazomib 4.0 mg | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 4: Sodium low | 0 Participants |
| Cohort 1: Ixazomib 4.0 mg | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 3: Sodium low | 1 Participants |
| Cohort 1: Ixazomib 4.0 mg | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 4: Potassium low | 0 Participants |
| Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 3: Sodium low | 0 Participants |
| Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 3: Neutrophils low | 2 Participants |
| Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 3: Hemoglobin low | 2 Participants |
| Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 3: Leukocytes low | 2 Participants |
| Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 3: Lymphocytes low | 3 Participants |
| Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 3: Platelets low | 2 Participants |
| Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 3: Albumin low | 1 Participants |
| Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 3: Corrected calcium high | 1 Participants |
| Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 4: Potassium low | 1 Participants |
| Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 3: Potassium low | 0 Participants |
| Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 3: Phosphate low | 1 Participants |
| Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 4: Neutrophils low | 2 Participants |
| Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 4: Leukocytes low | 1 Participants |
| Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 4: Lymphocytes low | 0 Participants |
| Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 4: Platelets low | 2 Participants |
| Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Grade 4: Sodium low | 1 Participants |
Primary
Number of Participants With Grade 3 or Higher TEAE Related to 12-lead Electrocardiograms (ECGs)
12-lead ECGs were graded using the CTCAE version 4.03. as: Grade 1 (Mild, asymptomatic or mild symptoms); Grade 2 (Moderate, minimal, local or noninvasive intervention indicated); Grade 3 (Severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated); Grade 4 (Life-threatening consequences, urgent intervention indicated); Grade 5 (Death related to AE).
Time frame: Baseline up to 29 days after last dose of study drug (up to Cycle 87 Day 44) (Each Cycle length=28 days)
Population: The safety analysis set consisted of all participants who received at least one dose of ixazomib.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1: Ixazomib 4.0 mg | Number of Participants With Grade 3 or Higher TEAE Related to 12-lead Electrocardiograms (ECGs) | 0 Participants |
| Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Number of Participants With Grade 3 or Higher TEAE Related to 12-lead Electrocardiograms (ECGs) | 0 Participants |
Primary
Number of Participants With Grade 3 or Higher TEAE Related to Body Weight
Body weight abnormalities were graded using the CTCAE version 4.03. as: Grade 1 (Mild, asymptomatic or mild symptoms); Grade 2 (Moderate, minimal, local or noninvasive intervention indicated); Grade 3 (Severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated); Grade 4 (Life-threatening consequences, urgent intervention indicated); Grade 5 (Death related to AE).
Time frame: Baseline up to 29 days after last dose of study drug (up to Cycle 87 Day 44) (Each Cycle length=28 days)
Population: The safety analysis set consisted of all participants who received at least one dose of ixazomib.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1: Ixazomib 4.0 mg | Number of Participants With Grade 3 or Higher TEAE Related to Body Weight | 0 Participants |
| Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Number of Participants With Grade 3 or Higher TEAE Related to Body Weight | 0 Participants |
Primary
Number of Participants With Grade 3 or Higher TEAE Related to Vital Signs
Vital signs were graded using the CTCAE version 4.03. as: Grade 1 (Mild, asymptomatic or mild symptoms); Grade 2 (Moderate, minimal, local or noninvasive intervention indicated); Grade 3 (Severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated); Grade 4 (Life-threatening consequences, urgent intervention indicated); Grade 5 (Death related to AE).
Time frame: Baseline up to 29 days after last dose of study drug (up to Cycle 87 Day 44) (Each Cycle length=28 days)
Population: The safety analysis set consisted of all participants who received at least one dose of ixazomib.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1: Ixazomib 4.0 mg | Number of Participants With Grade 3 or Higher TEAE Related to Vital Signs | 1 Participants |
| Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Number of Participants With Grade 3 or Higher TEAE Related to Vital Signs | 0 Participants |
Secondary
Number of Participants Who Achieved Complete Response (CR), Very Good Partial Response (VGPR), and Partial Response (PR)
Number of participants who achieved CR, PR, VGPR were assessed in accordance to International Myeloma Working Group Uniform Response Criteria for Multiple Myeloma. CR: No immunofixation on serum and urine, disappearance of soft tissue plasmacytomas and \<5% plasma cells in bone marrow. Normal serum free light chain (SFLC) ratio if disease measurable only by SFLC. VGPR: Serum and urine M-protein detectable by immunofixation but not electrophoresis or greater than or equal to (\>=) 90% decrease in serum M-protein with urine M-protein \<100 milligram per 24 hours (mg/24 hrs). If disease measurable only by SFLC, \>= 90% decrease in the difference between involved and uninvolved FLC levels (dFLC). PR: \>= 50% reduction of serum M-protein and \>= 90% reduction in urine M-protein or to \<200 mg/24 hrs, or a \>= 50% decrease in dFLC. A \>=50% decrease in the size of soft tissue plasmacytomas present at baseline
Time frame: Baseline up to 29 days after last dose of study drug (up to Cycle 87 Day 44) (Each Cycle length=28 days)
Population: The response evaluable analysis set consisted of all participants who received at least one dose of ixazomib, have measurable disease at baseline, and at least one postbaseline response assessment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1: Ixazomib 4.0 mg | Number of Participants Who Achieved Complete Response (CR), Very Good Partial Response (VGPR), and Partial Response (PR) | 0 Participants |
| Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Number of Participants Who Achieved Complete Response (CR), Very Good Partial Response (VGPR), and Partial Response (PR) | 2 Participants |